In July ----, Finland s Faron Pharmaceuticals entered into an agreement with Abzena whereby Abzena will manufacture Clevegen, a novel therapeutic antibody being developed by Faron to reduce immune suppression in cancer. In July ----, the National Coalition Party received criticism for its apparent reluctance to de-regulate and increase competition in the pharmacy industry. ...In July ----, the National Coalition Party received criticism for its apparent reluctance to de-regulate and increase competition in the pharmacy industry. Also in July ----, Finnish pharmaceutical manufacturers began testing new medicine packaging in preparation for new EU-wide measures targeting counterfeit medicines. In June ----, Weifa signed a five-year distribution agreement with the Finland-based Fysioline Group covering several of Weifa s most recently launched products within the pain category, and can be extended to include additional products. ...Also in July ----, Finnish pharmaceutical manufacturers began testing new medicine packaging in preparation for new EU-wide measures targeting counterfeit medicines. In June ----, Weifa signed a five-year distribution agreement with the Finland-based Fysioline Group covering several of Weifa s most recently launched products within the pain category, and can be extended to include additional products.
...Finland s Risk/Reward Index score for Q--- remains unchanged from last quarter, at --.- out of ---. However, the country has fallen from seventh to ninth position in our Western European matrix, just below Norway (--.-) and above Sweden (--.-). ...However, the country has fallen from seventh to ninth position in our Western European matrix, just below Norway (--.-) and above Sweden (--.-). Finland s strong emphasis on the regulatory environment is an appealing feature of the market, although a major factor affecting the business environment for drugmakers is its small overall market size. Increasing cost-containment measures also negatively affect the Industry Rewards score. ...Increasing cost-containment measures also negatively affect the Industry Rewards score. Nevertheless, high per capita drug expenditure means that companies operating in the country can see substantial income.
...Obesity boom to substantially increase non-communicable disease burden. ...Threats Impact of forthcoming patent expirations. As the government copies other European governments cost-containment measures operating conditions for drugmakers will become tougher over the long term. Despite a sluggish start, the potential of the domestic generics market will increasingly attract strong foreign competition, both from Europe and further afield. ...